Written By: Katherashala Dharan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Biohaven has completed enrollment in a Phase 2 proof-of-concept clinical trial evaluating its investigational myostatin-activin pathway inhibitor, taldefgrobep alfa, for the treatment of obesity. The company expects to report topline results from the study in the second half of 2026.
The randomized, double-blind, placebo-controlled Phase 2 study (NCT07281495) is designed to assess the efficacy and tolerability of taldefgrobep as monotherapy in adults living with overweight or obesity. Approximately 150 participants have been enrolled across 20 clinical sites in the United States. The trial is evaluating both once-weekly and once-monthly dosing regimens administered via a self-injectable autoinjector.
The study includes a 24-week double-blind treatment period followed by a 24-week open-label extension phase. The primary endpoint is the percentage change in total body weight from baseline to Week 24. Secondary endpoints include changes in total body fat mass and lean body mass, reflecting the program’s focus on improving body composition rather than weight loss alone.
Taldefgrobep is a fusion protein designed to inhibit signaling through activin transmembrane receptors (ActRII). By blocking signals from transforming growth factor-beta ligands such as myostatin and activins, the therapy aims to reduce adipose tissue while increasing or preserving lean muscle mass.
Earlier clinical research has shown encouraging changes in body composition with taldefgrobep. In a Phase 1 study (NCT02145234), participants experienced reductions in total body fat mass of more than 6% alongside increases in lean muscle mass of up to 4% after 29 days of dosing. The drug has also been evaluated in more than 700 clinical trial participants and has generally been well tolerated, with low rates of serious adverse events.
Reference
Biohaven’s Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment, 19 March 2026, Biohaven’s Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment | Biohaven, Ltd.
Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects, ClinicalTrials.gov ID NCT02145234, https://clinicaltrials.gov/study/NCT02145234
About the Writer
Katherashala Dharan Kumar, PharmD A dedicated Clinical Researcher with expertise in medical and scientific writing clinical trials, drug safety, and healthcare innovation. Actively contributes to research publications and clinical documentation focused on improving patient outcomes through evidence-based practices and ethical research standards. Believe that every complex data point has a human story waiting to be told. Focusing on providing actionable insights for clinical research.